Overview
The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be included. A comparison will be made between the effectiveness of intralesional Triamcinolone (standard first-line treatment) and intralesional Candida albicans antigen, with serial clinical and trichoscopic pictures at follow-up to evaluate the clinical response and associated adverse effects.
Eligibility
Inclusion Criteria:
- Diagnosis of alopecia areata
- SALT score of less than 50% extension
- Has not received any topical or systemic treatment in the last month
- Signed informed consent
Exclusion Criteria:
- Any skin condition on the scalp (infectious, inflammatory or neoplastic) that could modify the clinical of trichoscopic features
- Pregnancy or breast-feeding
- Patients in medications that could cause hair loss as side-effects